Fintel reports that on January 31, 2025, JMP Securities initiated coverage of Astria Therapeutics (NasdaqGM:ATXS) with a Market Outperform recommendation. Analyst Price Forecast Suggests 244.82% ...

On Friday, JMP Securities maintained a Market Perform rating on Uber Inc. (NYSE:UBER) without altering its price target. According to the firm, Uber's last closing price of $66.77 reflects a valuation ...

On Friday, JMP Securities initiated coverage on Astria Therapeutics (NASDAQ: ATXS), assigning a Market Outperform rating and setting a price target of $26.00. The stock, currently trading at $7.49, ...

On Friday, JMP Securities released a comprehensive fourth-quarter earnings preview for the Commercial Mortgage REIT and Commercial Real Estate Finance sector. The report, which covers 22 of the 24 ...

On Friday, JMP Securities maintained a Market Perform rating on Uber Inc. (NYSE:UBER) without altering its price target. According to the firm, Uber's last closing price of $66.77 reflects a ...

On Friday, JMP Securities maintained its Market Outperform rating on LegalZoom.com Inc (NASDAQ:LZ), reflecting confidence in the company's leading position in the business formations sector.

On Friday, JMP Securities initiated coverage on Astria Therapeutics (NASDAQ: ATXS), assigning a Market Outperform rating and setting a price target of $26.00. The stock, currently trading at $7.49 ...

JMP Securities tells investors in a research note. The firm is increasingly convinced that Uber (UBER) has to use M&A to buy autonomous vehicle technology to compete as Waymo scales its business ...

JMP Securities analyst Jonathan Wolleben raised the firm’s price target on Pharvaris (PHVS) to $55 from $46 and keeps an Outperform rating on the shares. Pharvaris is the only company with an ...

JMP Securities initiated coverage of KalVista (KALV) with an Outperform rating and $19 price target KalVista is developing sebetralstat, a small-molecule plasma kallikrein inhibitor, which could ...